一个PDE4短形降解剂:第一个异型特异性的PDE4抑制
1Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Canada.
新的蛋白质分解向嵌合体 (PROTACs) 选择性降解特定化酶4 (PDE4) 的简称. 这种高度选择性的方法提供了对循环AMP (cAMP) 信号和炎症的强有力的控制.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 固酶4 (PDE4) 抑制剂在临床上使用,但缺乏异型选择性,导致副作用.
- 由于所有PDE4酶中都保留了催化域,因此实现PDE4异型选择性是具有挑战性的.
研究的目的:
- 开发一种用于选择性降解特定的二酶4 (PDE4) 酶异型的新方法.
- 研究选择性PDE4降解对炎症事件和循环AMP (cAMP) 信号传递的影响.
主要方法:
- 设计和应用一个强大的基化酶4 (PDE4) 蛋白质分解向嵌合体 (PROTAC).
- 评估 PROTAC 能够选择性地诱导 PDE4 缩短形式的降解的能力.
- 评估针对性PDE4异构体调节的炎症途径的下游影响.
主要成果:
- 开发的PDE4 PROTAC在降解PDE4异型 (短型) 的子集方面表现出高选择性.
- 选择性降解PDE4短形式有效调节炎症事件.
- 这种有针对性的降解会影响循环AMP (cAMP) 信号通路.
结论:
- 蛋白质分解向嵌合体 (PROTACs) 提供了一种新的策略,可以在向PDE4异型时实现前所未有的选择性.
- 这种方法提供了一种强大的新方法来调节循环AMP (cAMP) 信号和炎症反应.
- 这种选择性降解技术可能预示着药理学的新时代,用于精确控制细胞信号.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
12:24Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
Published on: September 29, 2016
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
GPCR Desensitization
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Dipeptidyl Peptidase 4 Inhibitors
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Antihypertensive Drugs: Vasodilators
